Lumida
/AVNS
⌘K
Avanos Medical Inc

Avanos Medical Inc

AVNS
$24.99USD↑+0.04%+0.01 today

MARKET CAP

1.2B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$25 – $25

52W RANGE

$9
$25

AI Summary

Stalk
StalkMedium

AVNS remains in a Stage 2 advancing trend with a bullish structural bias. A Devil’s Bargain continuation pattern suggests potential near-term upside extension, but current consolidation above flat EMAs and overbought RSI indicate a likely pause. Price is tightly tracking above the 9EMA and 20EMA, offering potential pullback entry zones. On balance, the medium-term bias is bullish, but execution should be deferred until a favorable pullback into support.

  • ↑Specialty nutrition segment delivered 8% organic growth in 2025.
  • ↑Nexus Medical integration adds ~$5M revenue targeting double-digit growth.
  • ↓Tariffs impose ~$30M manufacturing costs in 2026, pressuring margins.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Avanos Medical (formerly AVNS) specializes in medical technologies with a focus on pain management and specialty nutrition systems. The company operates in a niche space within the healthcare industry, driven by its commitment to advancing non-opioid therapies and innovative solutions for patient care. Following its acquisition by American Industrial Partners in July 2026, Avanos is now privately held and seeks to enhance its market positioning by streamlining operations and focusing on high-growth segments.

Bull says

  • ↑Specialty nutrition segment delivered 8% organic growth in 2025.
  • ↑Nexus Medical integration adds ~$5M revenue targeting double-digit growth.
  • ↑Generated ~$43M free cash flow, funding R&D and M&A initiatives.
  • ↑Tariff mitigation measures aim to offset ~$30M in 2026 costs.
  • ↑CEO Pacitti’s streamlined operations and high-value product focus drive efficiency.
  • ↑Robust balance sheet delivers high ROI in pediatric nutrition markets.

Bear says

  • ↓Tariffs impose ~$30M manufacturing costs in 2026, pressuring margins.
  • ↓China exit execution risks could disrupt operations and cash flow.
  • ↓Pain management segment faced declines amid ongoing pricing pressures.
  • ↓Recorded $77M non-cash impairment in pain management, flagging overvaluation.
  • ↓Heavy reliance on specialty nutrition exposes Avanos to market shifts.
  • ↓Capex demands may exceed free cash flow during transition period.

Earnings Call · Q4 2024 · Mgmt. Guidance

Updated 09-11-2026neutral

Transcript signals

Bull points

  • We delivered a strong fourth quarter anchored by continued solid performance of our enteral feeding franchise.
  • we are pleased to have served over 2 million patients in 2024 through our enteral feeding portfolio, which provide essential nutrition and medication delivery for those in need, and our pain management and recovery solutions, which deliver clinically proven non-opioid therapies to support patients with chronic pain conditions or those recovering from postoperative pain.
  • Our NREL feeding portfolio continues to deliver above market results, growing almost 12% organically versus prior year, reaffirming our number one position in short-term, long-term, and neonatal feeding.

Bear points

  • Our fourth quarter gap results include a non-cash impairment charge of approximately $437 million based upon an assessment that the fair value of our single company reporting unit was below its carrying value.
  • Normalized organic sales for this quarter were down approximately 3%, excluding the impact of foreign exchange and our previously announced strategic decision to discontinue certain low-growth, low-margin products.
  • 20% decrease in HA revenue for the full year.
Read full transcript analysis ›